NASDAQ:SNOA Sonoma Pharmaceuticals (SNOA) Stock Price, News & Analysis $1.27 +0.03 (+2.01%) Closing price 03:59 PM EasternExtended Trading$1.28 +0.01 (+1.10%) As of 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsNews and TrendsOwnershipSEC Filings About Sonoma Pharmaceuticals Stock (NASDAQ:SNOA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Sonoma Pharmaceuticals alerts:Sign Up Key Stats Today's Range$1.24▼$1.2950-Day Range$1.10▼$1.4452-Week Range$0.85▼$4.60Volume24,295 shsAverage Volume53,692 shsMarket Capitalization$6.08 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Sonoma Pharmaceuticals, Inc. develops and commercializes non-antibiotic, non-steroidal products for wound care, dermatology, eye care, oral care and animal health. Its products are based largely on Microcyn technology, a stabilized hypochlorous-acid formulation designed for use in cleansing, managing and protecting damaged or irritated tissue. The company’s product portfolio has included wound cleansers and gels, dermatological treatments, scar-care products, ophthalmic solutions and veterinary products marketed under brands such as Microcyn, Dermacyn, Celacyn and MicrocynAH. These products are intended for applications including wound management, skin conditions, post-procedure care, eye discomfort and animal wound care. Sonoma Pharmaceuticals sells its products through distributors, commercial partners and other channels in the United States and selected international markets. The company was formerly known as Oculus Innovative Sciences and adopted the Sonoma Pharmaceuticals name in 2016.AI Generated. May Contain Errors. Read More Sonoma Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks4th Percentile Overall ScoreSNOA MarketRank™: Sonoma Pharmaceuticals scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.7 / 5Analyst RatingSell Consensus RatingSonoma Pharmaceuticals has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageSonoma Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.Read more about Sonoma Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Sonoma Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sonoma Pharmaceuticals is -1.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSonoma Pharmaceuticals has a P/B Ratio of 1.95. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Sonoma Pharmaceuticals' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.25% of the float of Sonoma Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverSonoma Pharmaceuticals has a short interest ratio ("days to cover") of 4.45.Change versus previous monthShort interest in Sonoma Pharmaceuticals has recently increased by 10.52%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSonoma Pharmaceuticals does not currently pay a dividend.Dividend GrowthSonoma Pharmaceuticals does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.36 News SentimentSonoma Pharmaceuticals has a news sentiment score of 0.36. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Sonoma Pharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for SNOA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows3 people have added Sonoma Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Sonoma Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders1.02% of the stock of Sonoma Pharmaceuticals is held by insiders.Percentage Held by Institutions1.95% of the stock of Sonoma Pharmaceuticals is held by institutions.Read more about Sonoma Pharmaceuticals' insider trading history. Receive SNOA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SNOA Stock News HeadlinesReviewing Sonoma Pharmaceuticals (NASDAQ:SNOA) and Indivior (NASDAQ:INDV)September 25 at 4:15 AM | americanbankingnews.comSCYNEXIS (NASDAQ:SCYX) vs. Sonoma Pharmaceuticals (NASDAQ:SNOA) Critical SurveySeptember 23 at 4:59 AM | americanbankingnews.comDo NOT Buy SpaceX – Do This InsteadSpaceX just went public - and Whitney Tilson, Harvard MBA and 30-year Wall Street veteran, says buying in could be a costly mistake. He calls it among the most overhyped, overvalued large-cap offerings ever pushed onto everyday investors. Tilson believes a rare economic event is approaching - one with serious consequences for your portfolio this summer. He has prepared a free analysis outlining what he sees and the specific steps he recommends taking now.September 25 at 1:00 AM | Stansberry Research (Ad)Head-To-Head Comparison: Lexaria Bioscience (NASDAQ:LEXX) and Sonoma Pharmaceuticals (NASDAQ:SNOA)September 22 at 6:30 AM | americanbankingnews.comSonoma Pharmaceuticals Cancels Adjourned Special Stockholder MeetingAugust 19, 2026 | tipranks.comSonoma Pharmaceuticals Turns EBITDA Positive for First Time with Record Quarterly RevenueAugust 6, 2026 | benzinga.comSonoma Pharmaceuticals Expands At-the-Market Equity Offering CapacityJune 18, 2026 | tipranks.comSonoma Pharmaceuticals, Inc.: Sonoma Pharmaceuticals Reports Fiscal Year and Fourth Quarter 2026 Financial ResultsJune 16, 2026 | finanznachrichten.deSee More Headlines SNOA Stock Analysis - Frequently Asked Questions How have SNOA shares performed this year? Sonoma Pharmaceuticals' stock was trading at $3.64 at the start of the year. Since then, SNOA stock has decreased by 65.1% and is now trading at $1.27. How were Sonoma Pharmaceuticals' earnings last quarter? Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its earnings results on Thursday, August, 6th. The company reported $0.02 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.30) by $0.32. The business had revenue of $6.41 million for the quarter, compared to the consensus estimate of $4.99 million. Sonoma Pharmaceuticals had a negative trailing twelve-month return on equity of 21.41% and a negative net margin of 10.33%. How do I buy shares of Sonoma Pharmaceuticals? Shares of SNOA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Sonoma Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), Meta Platforms (META), NVIDIA (NVDA), Bristol Myers Squibb (BMY), Advanced Micro Devices (AMD), Ford Motor (F) and PayPal (PYPL). Company Calendar Last Earnings8/06/2026Today9/25/2026Next Earnings (Estimated)11/16/2026Fiscal Year End3/31/2027Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (5m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 SNOA's financial health is in the Red zone, according to TradeSmith. SNOA has been in this zone for over 5 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:SNOA CIK1367083 Webwww.sonomapharma.com Phone(800) 759-9305Fax707-283-0551Employees260Year Founded1999Profitability EPS (Trailing Twelve Months)($1.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$3.17 million Net Margins-10.33% Pretax Margin-11.44% Return on Equity-21.41% Return on Assets-6.08% Debt Debt-to-Equity RatioN/A Current Ratio2.99 Quick Ratio2.29 Sales & Book Value Annual Sales$19.53 million Price / Sales0.31 Cash FlowN/A Price / Cash FlowN/A Book Value$0.65 per share Price / Book1.95Miscellaneous Outstanding Shares4,790,000Free Float4,739,000Market Cap$6.08 million OptionableNot Optionable Beta1.31 Social Links The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (NASDAQ:SNOA) was last updated on 9/25/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredHere’s Why Trump Won’t End The Iran WarTrump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...Banyan Hill Publishing | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored100% overnight gains?Rumors are circulating that Elon Musk is preparing to acquire three publicly traded companies. Dr. Mark Sko...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Sonoma Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Sonoma Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
